Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Sayegh

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
The Oncologist|June 22, 2021
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning PlatformEdwin Lin, Andrew W Hahn, Roberto H Nussenzveig, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Urology Practice|October 30, 2023
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway InhibitorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
Urology Practice|October 31, 2023
Reply by AuthorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
European Urology Focus|April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based CombinationsGeorges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
The Oncologist|June 22, 2021
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning PlatformEdwin Lin, Andrew W Hahn, Roberto H Nussenzveig, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Urology Practice|October 30, 2023
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway InhibitorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
Urology Practice|October 31, 2023
Reply by AuthorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
European Urology Focus|April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based CombinationsGeorges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
Pageof 8